Neurocrine Q2 INGREZZA sales $580M (+32% YoY); raises FY guidance; CEO Gorman to retire Oct 11

NEUROCRINE BIOSCIENCES INC

2024-Q2 EPS reported $1.04 revenue$1,105,500,000

INGREZZA Q2 net product sales $580M (+32% YoY); FY 2024 guidance raised to $2.25-$2.3B.
GAAP net income $65M ($0.63 EPS); Non-GAAP net income $168.9M ($1.63 EPS), vs $125.7M ($1.25) YoY.
CEO Kevin Gorman to retire Oct 11, 2024; succeeded by Kyle Gano, current Chief Business Development Officer.
FDA granted Priority Review for crinecerfont in CAH; PDUFA Dec 29 (capsule) and Dec 30 (oral solution) 2024.
Top-line Phase 2 data for NBI-'568 (schizophrenia) and luvadaxistat (CIAS) on track for Q3 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.